2009
Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors
Kobayashi K, Szklaruk J, Trent JC, Ensor J, Ahrar K, Wallace MJ, Madoff DC, Murthy R, Hicks ME, Gupta S. Hepatic Arterial Embolization and Chemoembolization for Imatinib-Resistant Gastrointestinal Stromal Tumors. American Journal Of Clinical Oncology 2009, 32: 574-581. PMID: 19636238, DOI: 10.1097/coc.0b013e31819cca35.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic AgentsBenzamidesDrug Resistance, NeoplasmEmbolization, TherapeuticFemaleGastrointestinal NeoplasmsGastrointestinal Stromal TumorsHepatic ArteryHumansImatinib MesylateLiver NeoplasmsMaleMiddle AgedNeoplasm StagingPiperazinesPrognosisProtein-Tyrosine KinasesPyrimidinesRetrospective StudiesSurvival RateTreatment OutcomeConceptsImatinib-resistant gastrointestinal stromal tumorsGastrointestinal stromal tumorsProgressive liver metastasesHepatic arterial embolizationResponse Evaluation CriteriaOverall survival rateStromal tumorsArterial embolizationLiver metastasesSurvival rateRadiologic responseStable diseaseExtrahepatic metastasesPartial responseSurvival timeMedian progression-free survival timeSolid tumorsProgression-free survival ratesMedian overall survival timeProgression-free survival timeResponse criteriaCox proportional hazards modelAppreciable survival benefitEfficacy of embolotherapyProgression-free survival
2006
Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors
Kobayashi K, Gupta S, Trent JC, Vauthey J, Krishnamurthy S, Ensor J, Ahrar K, Wallace MJ, Madoff DC, Murthy R, McRae SE, Hicks ME. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors. Cancer 2006, 107: 2833-2841. PMID: 17096432, DOI: 10.1002/cncr.22336.Peer-Reviewed Original ResearchConceptsHepatic artery chemoembolizationGastrointestinal stromal tumorsUse of imatinibOverall survivalOS timeLiver diseaseStromal tumorsTumor responseMetastatic gastrointestinal stromal tumorsExtensive liver involvementMedian OS timeObjective tumor responseMedian PFS timeProgression-free survivalKaplan-Meier methodMajority of patientsDurable tumor responsesExtrahepatic diseaseOS ratesRadiologic responseStable diseaseDisease stabilizationPFS timeExtrahepatic metastasesLiver involvement